These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

544 related items for PubMed ID: 24384723

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Heat shock factor 1 confers resistance to lapatinib in ERBB2-positive breast cancer cells.
    Yallowitz A, Ghaleb A, Garcia L, Alexandrova EM, Marchenko N.
    Cell Death Dis; 2018 May 24; 9(6):621. PubMed ID: 29799521
    [Abstract] [Full Text] [Related]

  • 4. A gain-of-function mutant p53-HSF1 feed forward circuit governs adaptation of cancer cells to proteotoxic stress.
    Li D, Yallowitz A, Ozog L, Marchenko N.
    Cell Death Dis; 2014 Apr 24; 5(4):e1194. PubMed ID: 24763051
    [Abstract] [Full Text] [Related]

  • 5. Heat shock factor Hsf1 cooperates with ErbB2 (Her2/Neu) protein to promote mammary tumorigenesis and metastasis.
    Xi C, Hu Y, Buckhaults P, Moskophidis D, Mivechi NF.
    J Biol Chem; 2012 Oct 12; 287(42):35646-35657. PubMed ID: 22847003
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Hsp90-stabilized MIF supports tumor progression via macrophage recruitment and angiogenesis in colorectal cancer.
    Klemke L, De Oliveira T, Witt D, Winkler N, Bohnenberger H, Bucala R, Conradi LC, Schulz-Heddergott R.
    Cell Death Dis; 2021 Feb 04; 12(2):155. PubMed ID: 33542244
    [Abstract] [Full Text] [Related]

  • 8. Amplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human epidermal growth factor receptor 2 negative breast cancer.
    Cheng Q, Chang JT, Geradts J, Neckers LM, Haystead T, Spector NL, Lyerly HK.
    Breast Cancer Res; 2012 Apr 17; 14(2):R62. PubMed ID: 22510516
    [Abstract] [Full Text] [Related]

  • 9. Upregulation of lactate dehydrogenase A by ErbB2 through heat shock factor 1 promotes breast cancer cell glycolysis and growth.
    Zhao YH, Zhou M, Liu H, Ding Y, Khong HT, Yu D, Fodstad O, Tan M.
    Oncogene; 2009 Oct 22; 28(42):3689-701. PubMed ID: 19668225
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Heat-shock transcription factor HSF1 has a critical role in human epidermal growth factor receptor-2-induced cellular transformation and tumorigenesis.
    Meng L, Gabai VL, Sherman MY.
    Oncogene; 2010 Sep 16; 29(37):5204-13. PubMed ID: 20622894
    [Abstract] [Full Text] [Related]

  • 13. Insights from yeast into whether the inhibition of heat shock transcription factor (Hsf1) by rapamycin can prevent the Hsf1 activation that results from treatment with an Hsp90 inhibitor.
    Millson SH, Piper PW.
    Oncotarget; 2014 Jul 15; 5(13):5054-64. PubMed ID: 24970820
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Ganetespib targets multiple levels of the receptor tyrosine kinase signaling cascade and preferentially inhibits ErbB2-overexpressing breast cancer cells.
    Lee H, Saini N, Howard EW, Parris AB, Ma Z, Zhao Q, Zhao M, Liu B, Edgerton SM, Thor AD, Yang X.
    Sci Rep; 2018 May 01; 8(1):6829. PubMed ID: 29717218
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Targeting HSF1 sensitizes cancer cells to HSP90 inhibition.
    Chen Y, Chen J, Loo A, Jaeger S, Bagdasarian L, Yu J, Chung F, Korn J, Ruddy D, Guo R, McLaughlin ME, Feng F, Zhu P, Stegmeier F, Pagliarini R, Porter D, Zhou W.
    Oncotarget; 2013 Jun 01; 4(6):816-29. PubMed ID: 23615731
    [Abstract] [Full Text] [Related]

  • 20. Anticancer activity of Celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers.
    Raja SM, Clubb RJ, Ortega-Cava C, Williams SH, Bailey TA, Duan L, Zhao X, Reddi AL, Nyong AM, Natarajan A, Band V, Band H.
    Cancer Biol Ther; 2011 Jan 15; 11(2):263-76. PubMed ID: 21088503
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.